Novo Nordisk A/S

NYSE: NVO · Real-Time Price · USD
52.44
1.49 (2.92%)
At close: Aug 15, 2025, 3:59 PM
52.97
1.01%
After-hours: Aug 15, 2025, 05:51 PM EDT

Novo Nordisk A/S Balance Sheet Statement

Financials in DKK. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Cash & Equivalents
15.65B 14.39B 12.65B 10.72B
Short-Term Investments
10.65B 15.84B 10.92B 6.76B
Long-Term Investments
2.68B 1.66B 1.34B 1.44B
Other Long-Term Assets
4.02B 1.43B 206M 267M
Receivables
87.41B 75.26B 57.51B 46.8B
Inventory
40.85B 31.81B 24.39B 19.62B
Other Current Assets
6.33B 2.34B 9.67B 7.85B
Total Current Assets
160.9B 139.65B 108.19B 85.59B
Property-Plant & Equipment
162.49B 90.96B 66.67B 55.36B
Goodwill & Intangibles
111.09B 60.41B 51.42B 43.17B
Total Long-Term Assets
304.9B 174.84B 133.06B 108.91B
Total Assets
465.8B 314.49B 241.26B 194.51B
Account Payables
28.85B 25.61B 15.59B 8.87B
Deferred Revenue
n/a n/a n/a 55.18B
Short-Term Debt
11.78B 5.3B 480M 12.86B
Other Current Liabilities
165.85B 38.14B 103.89B 21.78B
Total Current Liabilities
217.53B 169.66B 120.94B 99.52B
Long-Term Debt
84.25B 15.98B 20.77B 9.65B
Other Long-Term Liabilities
9.68B 7.58B 5.45B 360M
Total Long-Term Liabilities
104.78B 38.27B 36.83B 24.25B
Total Liabilities
322.31B 207.93B 157.77B 123.76B
Total Debt
102.79B 27.01B 25.78B 26.64B
Common Stock
446M 451M 456M 462M
Retained Earnings
144.45B 104.84B 80.59B 72B
Comprehensive Income
-1.41B 1.28B 2.45B -1.71B
Shareholders Equity
143.49B 106.56B 83.49B 70.75B
Total Investments
13.33B 17.5B 12.26B 8.21B